Ewing sarcoma is not inherited in the traditional sense. The genetic change that drives it, a chromosomal translocation that fuses two genes together, happens spontaneously in a cell during a person’s lifetime rather than being passed down from a parent. That said, inherited genetic variation does appear to influence who is susceptible to developing it, making the full answer more nuanced than a simple yes or no.
The Mutation That Causes Ewing Sarcoma
In about 85% of Ewing sarcoma cases, a piece of chromosome 22 swaps places with a piece of chromosome 11. This shuffle fuses two genes, called EWSR1 and FLI1, into a single abnormal gene that doesn’t exist in normal human cells. The resulting fusion protein acts as a powerful switch, turning on genes that drive uncontrolled cell growth and turning off genes that would normally keep cells in check. This fusion protein is both necessary for the tumor to survive and sufficient to transform normal cells into cancerous ones in laboratory experiments.
This translocation is somatic, meaning it occurs in a single cell at some point after conception. It is not present in the egg or sperm that formed the person, which is why it cannot be passed from parent to child. Every Ewing sarcoma tumor carries this rearrangement, and detecting it is actually how doctors confirm the diagnosis, typically using a laboratory technique called FISH that can visualize the broken and rejoined chromosomes under a microscope.
Why Some People Are More Susceptible
Even though the translocation itself is acquired, the background genetics you’re born with appear to influence whether that translocation is likely to happen and whether it successfully produces a tumor. Genome-wide association studies led by National Cancer Institute investigators have identified six regions in the genome where common inherited variants increase Ewing sarcoma risk. These variants carry surprisingly strong effects for a cancer study, with each one raising risk by about 1.7-fold. More notably, some of these inherited variants appear to interact directly with the EWSR1-FLI1 fusion protein, suggesting that certain people’s genetic makeup makes their cells more hospitable to the fusion gene once it forms.
The clearest evidence that inherited genetics play a role comes from the striking differences in incidence across racial and ethnic groups. Ewing sarcoma overwhelmingly affects people of European descent. Black individuals have roughly a 14-fold lower risk compared to non-Hispanic white individuals. Asian and Hispanic individuals also have significantly reduced risk, with odds roughly 40% and 27% lower, respectively. Hispanic individuals fall in between, with an intermediate incidence. These differences are too large and too consistent to be explained by environment alone, and researchers believe that variations in repetitive DNA sequences across ancestral populations partly explain why the critical translocation occurs far less often in people of African and Asian descent.
Family History and Cancer Risk
Ewing sarcoma itself almost never clusters in families. In one large study examining relatives of Ewing sarcoma patients, not a single case of Ewing sarcoma was found among first-, second-, or third-degree relatives. You won’t inherit Ewing sarcoma from a parent, and having a child with Ewing sarcoma does not mean siblings are at meaningful risk for the same disease.
However, relatives of Ewing sarcoma patients do show increased rates of other cancers. First-degree relatives (parents, siblings, children) had significantly elevated risks for brain, lung, female genital, and prostate cancers. Second-degree relatives showed higher rates of breast cancer, non-Hodgkin lymphoma, and certain other sarcomas. Even third-degree relatives had elevated rates of stomach cancer, prostate cancer, and acute lymphocytic leukemia. Because these relatives were not exposed to the chemotherapy or radiation used to treat Ewing sarcoma, these elevated risks point to some shared inherited predisposition to cancer more broadly, not to the Ewing sarcoma translocation itself.
Genetic Testing for Patients and Families
There are currently no uniform guidelines telling doctors exactly when to recommend germline genetic testing (testing for inherited mutations) in sarcoma patients. Testing is formally recommended for a few specific sarcoma subtypes, but Ewing sarcoma is not yet one of them. In practice, many cancer centers will offer genetic counseling if a patient has a strong family history of cancer or if testing reveals a potentially inherited mutation during tumor analysis. When such mutations are found, first-degree relatives may be offered “cascade testing” to see if they carry the same variant, which can inform cancer screening decisions.
For the tumor itself, molecular testing is standard. Doctors use FISH or a related technique called RT-PCR to confirm the EWSR1 gene rearrangement. This is a diagnostic test performed on tumor tissue to verify the Ewing sarcoma diagnosis, not a blood test for inherited risk. It identifies the somatic translocation that defines the disease and can also provide information about the specific fusion subtype, which may carry prognostic value.
Putting It Together
Ewing sarcoma sits in a middle ground that can feel confusing. The direct cause, the chromosomal translocation, is not inherited. But the soil in which that translocation takes root is shaped by your inherited DNA. Common genetic variants influence susceptibility, ancestral background dramatically affects incidence, and families of patients show broader cancer risk patterns that suggest shared genetic factors. So while you cannot “carry” Ewing sarcoma or pass it to your children, your genetic background does influence how likely it is to develop in the first place.